Impetigo Clinical Trial
Official title:
Ph-III Randomized, Multicentric, Controlled , Non-inferiority Trial to Evaluate the Safety and Efficacy of Mupirocin Gel 20 mg/g Versus Mupirocin Ointment 20 mg/g and Placebo in the Treatment of Impetigo in Paediatric Population
Verified date | March 2021 |
Source | Reig Jofre Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the study is to show non inferiority in terms of safety and efficacy of topical administration BID (Twice daily) of Mupirocin Gel 20 mg/g compared to topical administration of Mupirocin Ointment 20 mg/g TID (three times daily) (Bactroban) in the treatment of impetigo in paediatric population.
Status | Completed |
Enrollment | 467 |
Est. completion date | November 2016 |
Est. primary completion date | November 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Months to 15 Years |
Eligibility | Inclusion Criteria: - Age between 18 months and 15 years at the signature of informed consent - Impetigo susceptible to be treated with topical mupirocin and non requiring systemic antibiotic treatment (maximum of 4 different affected areas and no fever). - Global score of Skin Infection Rating Scale (SIRS) = 4, with positive value (= 1) in at least 3 of the 5 categories evaluated. - Signature of informed consent by parent or legal tutor and, in case of mature minor (12 years or more), signature of informed assent. - Patient or parent's ability to understand and fulfill with protocol requirements. - In potentially pregnant patients, negative pregnancy urine test at baseline and use of reliable contraception double barrier methods during the trial. Exclusion Criteria: - Allergy to any compound of the trial treatments - Have received systemic treatment with antibiotics or steroids, during the week prior to the baseline visit. - Have received topical treatment with corticosteroids, antibiotics or antifungals, during the 48 hours prior to the baseline visit. - Primary or secondary immunodeficiency. - Have received cytostatic or immunosuppressive treatment three months prior to baseline. - Any skin disorder that could interfere with the evaluation of the results of impetigo, such as presence of staphylococcal or streptococcal ecthyma, cellulitis, furunculosis, acute dermatitis, contact dermatitis or impetiginized eczema. - Diabetes mellitus. - Infection that, in the investigator's opinion, should be treated with systemic antibiotic. - Any medical condition which, in the investigator's opinion, contraindicates the subject's participation in the trial. - Forecast of little cooperation, non-compliance with medical treatment or low credibility. - Have participated in any clinical investigation with medicine within 30 days prior to basal visit. |
Country | Name | City | State |
---|---|---|---|
Spain | H.U. Sureste | Arganda del Rey | Madrid |
Spain | CAP Vallcarca-St. Gervasi | Barcelona | Catalonia |
Spain | CAP Corbera de Llobregat | Corbera De Llobregat | Catalonia |
Spain | CAP Castilla la Nueva | Fuenlabrada | Madrid |
Spain | H.U. Fuenlabrada | Fuenlabrada | Madrid |
Spain | CAP Amadeu Torner | L'Hospitalet De Llobregat | Catalonia |
Spain | CAP Florida Nord | L'HOspitalet de Llobregat | Catalonia |
Spain | CAP Mossèn Cinto Verdager | L'Hospitalet de Llobregat | Catalonia |
Spain | CAP Rambla Ferran | Lleida | Catalonia |
Spain | CAP Aravaca | Madrid | |
Spain | CAP Campo de la Paloma | Madrid | |
Spain | CAP Cea Bermúdez | Madrid | |
Spain | CAP La Calesas | Madrid | |
Spain | Hospital Gregorio MArañón | Madrid | |
Spain | CAP Pinto | Pinto | Madrid |
Spain | CAP Pozuelo de Alarcón | Pozuelo de Alarcón | Madrid |
Spain | H.U. Infanta Sofía | San Sebastián de los Reyes | Madrid |
Spain | CAP La Algaba | Sevilla | Andalucia |
Spain | CAP Torreblanca | Sevilla | Andalucia |
Spain | CAP Maria Bernades | Viladecans | Catalonia |
Lead Sponsor | Collaborator |
---|---|
Reig Jofre Group |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical cure at the end of treatment by SIRS assessed by blind observer | Proportion of subjects with clinical cure at the Day 8 visit, assessed by blind observer, according to criteria described in the Protocol (SIRS < or = 2). | Day 8 | |
Primary | Clinical cure as assessed by the proportion of subjects with no additional antibiotic therapy required to treat impetigo at day 8 | proportion of subjects with no additional antibiotic therapy required to treat impetigo | Day 8 | |
Secondary | Clinical cure at the end of follow up by SIRS assessed by blind observer | Proportion of subjects with clinical cure at the Day 14 visit, assessed by blind observer, according to criteria described in the protocol (SIRS < or = 2). | Day14 | |
Secondary | Clinical cure as assessed by the proportion of subjects with no additional antibiotic therapy required to treat impetigo at day 14 | proportion of subjects with no additional antibiotic therapy required to treat impetigo | Day14 | |
Secondary | Total SIRS score at the end of treatment and follow-up by blind observer | Day 8 and 14 | ||
Secondary | Bacteriology cure at follow-up | Bacteriology eradication at the end of follow-up period according to culture at screening and follow up visits | Day 14 | |
Secondary | Clinical cure at the end of treatment and follow-up by investigator | Proportion of subjects with clinical cure at the Day 8 and Day 14 visits, assessed by investigator, according to protocol criteria. | Day 8 and 14 | |
Secondary | SIRS total score at the end of treatment and follow-up by investigator | SIRS total Score at Day 8 and Day 14 visits, assessed by the investigator | Day 8 and 14 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00884728 -
Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern Territory
|
N/A | |
Completed |
NCT02902822 -
Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo
|
N/A | |
Completed |
NCT01153828 -
EU PV for Retapamulin-Prescribing
|
N/A | |
Active, not recruiting |
NCT05226260 -
Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary Care
|
N/A | |
Terminated |
NCT00986856 -
Fucidin® Cream in the Treatment of Impetigo
|
Phase 4 | |
Completed |
NCT01397461 -
Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo
|
Phase 3 | |
Recruiting |
NCT02090764 -
Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo
|
Phase 3 | |
Completed |
NCT02775617 -
Azithromycin - Ivermectin Mass Drug Administration for Skin Disease
|
Phase 4 | |
Not yet recruiting |
NCT01611909 -
Citriodiol® and Impetigo
|
Phase 2/Phase 3 | |
Completed |
NCT03177993 -
Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji
|
N/A | |
Completed |
NCT03429595 -
Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo
|
Phase 2 | |
Completed |
NCT00626795 -
Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)
|
Phase 2 | |
Completed |
NCT00758862 -
The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo
|
Phase 2 | |
Recruiting |
NCT01943136 -
The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial
|
Phase 1 | |
Completed |
NCT01670032 -
Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo
|
Phase 2/Phase 3 | |
Completed |
NCT01171326 -
Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients
|
Phase 2 | |
Completed |
NCT01367314 -
Safety and Efficacy of Topical NVC-422 Gel in Impetigo
|
Phase 2 | |
Completed |
NCT01126268 -
Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection
|
Phase 4 | |
Completed |
NCT00852540 -
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
|
Phase 3 | |
Completed |
NCT00133848 -
Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment
|
Phase 3 |